Real-World Outcomes With Generic Pomalidomide in Relapsed Refractory Multiple Myeloma-Experience From a Tertiary Care Cancer Center.
Suresh Kumar BondiliBhausaheb BagalAbhinav ZawarPradeep VentrapatiJayashree ThoratAnant GokarnSachin PunatarLingaraj NayakAvinash BondaHashmukh JainManju SengarNavin KhattryPublished in: JCO global oncology (2021)
Generic pomalidomide-based therapy is an effective option and is well tolerated in patients with RRMM. Higher response rates and longer survival seen in our study are possibly because of heterogeneity of the study population.